T. Rowe Price Investment Management, Inc. Vaxcyte, Inc. Transaction History
T. Rowe Price Investment Management, Inc.
- $162 Billion
- Q4 2024
A detailed history of T. Rowe Price Investment Management, Inc. transactions in Vaxcyte, Inc. stock. As of the latest transaction made, T. Rowe Price Investment Management, Inc. holds 2,860,717 shares of PCVX stock, worth $94.1 Million. This represents 0.14% of its overall portfolio holdings.
Number of Shares
2,860,717
Previous 4,053,828
29.43%
Holding current value
$94.1 Million
Previous $463 Million
49.45%
% of portfolio
0.14%
Previous 0.28%
Shares
9 transactions
Others Institutions Holding PCVX
# of Institutions
351Shares Held
126MCall Options Held
539KPut Options Held
253K-
Vanguard Group Inc Valley Forge, PA12MShares$394 Million0.02% of portfolio
-
Janus Henderson Group PLC London, X010.6MShares$348 Million0.46% of portfolio
-
Black Rock Inc. New York, NY9.94MShares$327 Million0.02% of portfolio
-
Ra Capital Management, L.P. Boston, MA8.69MShares$286 Million11.52% of portfolio
-
Capital Research Global Investors Los Angeles, CA6.21MShares$204 Million0.11% of portfolio
About Vaxcyte, Inc.
- Ticker PCVX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,315,100
- Market Cap $1.95B
- Description
- Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...